Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Abivax S.A.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: GSK’s R&D head departs; Bayer’s pharma R&D chief prioritizes assets; new US launches in atopic dermatitis; is Abivax an M&A target; and China’s gene therapy developers rush to the clinic.
AbiVax’s Partnering Prospects For MicroRNA-based Drug Boosted By Rheumatoid Arthritis Data
Now that AbiVax's novel anti-inflammatory ABX464 has demonstrated solid safety and efficacy in rheumatoid arthritis and ulcerative colitis, the French biotech is exploring additional programs in chronic inflammatory indications – and looking for a partner.
AbiVax Poised For 'Transformational' Q2
Q2 promises to be ‘transformational’ for AbiVax, propelled by key readouts for investigational anti-inflammatory, ABX464, and cancer agent, ABX196, but more funds will be needed by year end.
Roche’s Etrolizumab Failure ‘Removes Big Pipeline Opportunity’
Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.